Jiangsu Aidea Pharmaceutical Group (688488.SH) plans to raise no more than 1.277 billion yuan through a private placement.

date
21:24 02/03/2026
avatar
GMT Eight
Ady pharmaceutical (688488.SH) disclosed a plan to issue A-shares to specific investors, including up to 35 investors (including Mr. Fu Heliang, one of the actual controllers of the company) who meet the conditions stipulated by the China Securities Regulatory Commission and the Shanghai Stock Exchange. The total amount of funds raised will not exceed 1.277 billion yuan, and the net amount of funds raised after deducting the issuance expenses will be used for: the global clinical development project of new HIV integrase inhibitors (INSTI), the acquisition of 22.2324% equity of Nan Pharmaceutical from minority shareholders, and supplementing working capital.
Jiangsu Aidea Pharmaceutical Group (688488.SH) disclosed a preliminary plan to issue A shares to specific investors, including Mr. Fu Heliang, one of the company's actual controllers, and no more than 35 (inclusive of 35) investors who meet the conditions specified by the China Securities Regulatory Commission and the Shanghai Stock Exchange. The total amount of funds to be raised will not exceed (including) 1.277 billion yuan. The net amount of funds raised after deducting the issuance expenses will be used for the following purposes: global clinical development project of a new HIV integrase inhibitor (INSTI), acquisition of 22.2324% equity of Nanjing Pharmaceutical Industry from minority shareholders, and supplementing working capital.